- The partnership will leverage Veranova’s empirical manufacturing dataset and Phorum.AI’s generative AI to develop a tool for rapid development of optimised manufacturing processes.
- The collaboration aims to reduce costs, speed up development timelines, and reduce the environmental footprint of biopharmaceutical companies.
Veranova and Phorum.AI have announced a collaboration aimed at optimising pharmaceutical manufacturing processes using artificial intelligence (AI). The partnership will leverage Veranova’s extensive empirical manufacturing dataset, developed over two decades of manufacturing a portfolio of owned active pharmaceutical ingredient (API) drug master files (DMFs), and Phorum.AI’s generative AI.
The goal of the collaboration is to develop a tool that enables the development of optimised manufacturing processes in a fraction of the time compared to traditional methods. This could potentially reduce costs, speed up development timelines, and reduce the environmental footprint of biopharmaceutical companies.
Mike Riley, CEO of Veranova, expressed his enthusiasm for the partnership, stating, “Phorum.AI and Veranova have the potential to create a step change in the quality and development efficiency of pharmaceutical processing. We are delighted to partner with a leading AI technology innovator to be able to offer our clients a new capability that has the potential to develop optimised manufacturing processes at an accelerated pace.”
Dan Chinnapen, CEO of Phorum.AI, also shared his excitement about the partnership, saying, “By partnering with Veranova, a worldwide leader in developing and manufacturing APIs, we are able to more rapidly scale our market footprint and create greater impact sooner. We are excited to reduce time to market and mitigate costs for much-needed therapeutics.”
The two companies are collaborating on a commercial partnership that enables Veranova clients to benefit from an integrated scale-up solution powered by Phorum.AI’s technology. This partnership represents a significant step forward in the use of AI in pharmaceutical manufacturing, particularly in the area of contract manufacturing (CDMO). It is a clear demonstration of how AI can be leveraged to optimise processes and deliver benefits to the industry.
Stay ahead of trends and best practices
